Your browser doesn't support javascript.
loading
The Pediatric Crohn Disease Morbidity Index (PCD-MI): Development of a Tool to Assess Long-Term Disease Burden Using a Data-Driven Approach.
Ashton, James J; Gurung, Abhilasha; Davis, Cai; Seaby, Eleanor G; Coelho, Tracy; Batra, Akshay; Afzal, Nadeem A; Ennis, Sarah; Beattie, R Mark.
Afiliação
  • Ashton JJ; From the Department of Human Genetics and Genomic Medicine, University of Southampton, Southampton, UK.
  • Gurung A; the Department of Paediatric Gastroenterology, Southampton Children's Hospital, Southampton, UK.
  • Davis C; the Department of Paediatric Gastroenterology, Southampton Children's Hospital, Southampton, UK.
  • Seaby EG; NIHR Southampton Biomedical Research Centre, University Hospital Southampton, Southampton, UK.
  • Coelho T; From the Department of Human Genetics and Genomic Medicine, University of Southampton, Southampton, UK.
  • Batra A; the Department of Paediatric Gastroenterology, Southampton Children's Hospital, Southampton, UK.
  • Afzal NA; the Department of Paediatric Gastroenterology, Southampton Children's Hospital, Southampton, UK.
  • Ennis S; the Department of Paediatric Gastroenterology, Southampton Children's Hospital, Southampton, UK.
  • Beattie RM; From the Department of Human Genetics and Genomic Medicine, University of Southampton, Southampton, UK.
J Pediatr Gastroenterol Nutr ; 77(1): 70-78, 2023 07 01.
Article em En | MEDLINE | ID: mdl-37079872
ABSTRACT
BACKGROUND/

OBJECTIVE:

Heterogeneity and chronicity of Crohn disease (CD) make prediction of outcomes difficult. To date, no longitudinal measure can quantify burden over a patient's disease course, preventing assessment and integration into predictive modeling. Here, we aimed to demonstrate the feasibility of constructing a data driven, longitudinal disease burden score.

METHODS:

Literature was reviewed for tools used in assessment of CD activity. Themes were identified to construct a pediatric CD morbidity index (PCD-MI). Scores were assigned to variables. Data were extracted automatically from the electronic patient records at Southampton Children's Hospital, diagnosed from 2012 to 2019 (inclusive). PCD-MI scores were calculated, adjusted for duration of follow up and assessed for variation (ANOVA) and distribution (Kolmogorov-Smirnov).

RESULTS:

Nineteen clinical/biological features across five themes were included in the PCD-MI including blood/fecal/radiological/endoscopic results, medication usage, surgery, growth parameters, and extraintestinal manifestations. Maximal score was 100 after accounting for follow-up duration. PCD-MI was assessed in 66 patients, mean age 12.5 years. Following quality filtering, 9528 blood/fecal test results and 1309 growth measures were included. Mean PCD-MI score was 14.95 (range 2.2-32.5); data were normally distributed ( P = 0.2) with 25% of patients having a PCD-MI < 10. There was no difference in the mean PCD-MI when split by year of diagnosis, F -statistic 1.625, P = 0.147.

CONCLUSIONS:

PCD-MI is a calculatable measure for a cohort of patients diagnosed over an 8-year period, integrating a wide-range of data with potential to determine high or low disease burden. Future iterations of the PCD-MI require refinement of included features, optimized scores, and validation on external cohorts.
Assuntos

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Doença de Crohn Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Child / Humans Idioma: En Revista: J Pediatr Gastroenterol Nutr Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Doença de Crohn Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Child / Humans Idioma: En Revista: J Pediatr Gastroenterol Nutr Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Reino Unido